Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1517 of 5804
-
Could a 3-Day course ease chronic fatigue? new trial aims to find out
Symptom relief Recruiting nowChronic fatigue syndrome/Myalgic encephalomyelitis (CFS/ME) can be a serious and disabling condition with a heavy symptom burden and low function. Work disability is common, and social life dramatically affected. CFS/ME is a challenging health problem as well as a societal proble…
Phase: NA • Sponsor: Norwegian University of Science and Technology • Aim: Symptom relief
Last updated Jun 27, 2026 08:00 UTC
-
Can an Iron-Binding drug protect the brain after a severe stroke?
Disease control Recruiting nowAneurysmal subarachnoid hemorrhage (aSAH) has a high incidence of mortality and significant morbidity, with mortality exceeding 30% in the first two days.The initial injury is related to increasing intracranial pressure, cerebral edema, and neuronal injuries associated with the r…
Phase: PHASE2 • Sponsor: Aditya S. Pandey, MD • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Fourth COVID shot may shield seniors from severe illness
Disease control CompletedThe objective of this observational case-crossover study is to evaluate the effectiveness, safety and immunogenicity of the second booster dose in the elderly. There are an estimated 490,000 eligible individuals aged 60 and over statewide for the effectiveness study. Two hundred …
Sponsor: Federal University of Espirito Santo • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New antibody shows promise for Tough-to-Treat hodgkin lymphoma
Disease control CompletedThe study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of sabestomig (AZD7789) in patients with relapsed/refractory classical Hodgkin Lymphoma (r/r cHL).
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Could a simple pill calm brain inflammation and slow Alzheimer's?
Disease control Recruiting nowDevelopment of novel disease-modifying therapies for Alzheimer's disease (AD) remains of paramount importance. This study will be a Phase II randomized clinical trial testing Senicapoc in patients with mild or prodromal AD. This will be a small Proof of Mechanism study to prove b…
Phase: PHASE2 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New scan could spot deadliest prostate cancers
Diagnosis OngoingCD46 is an exciting new therapeutic target in prostate cancer, with the antibody drug conjugate FOR46 under investigation in phase I clinical trials. The hypothesis of the study is that CD46 expression, measured via our novel imaging biomarker, is a characteristic feature of mCRP…
Phase: PHASE1 • Sponsor: Robert Flavell, MD, PhD • Aim: Diagnosis
Last updated Jun 27, 2026 11:02 UTC
-
New drug shows promise against rare skin cancer
Disease control OngoingThis phase II trial studies the effect of pomalidomide in treating patients with Kaposi sarcoma. Pomalidomide is a cancer fighting drug that stops the growth of blood vessels, stimulates the immune system, and may kill cancer cells.
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Robot suit and zaps may boost walking after spinal injury
Symptom relief Recruiting nowWhile there are a number of prospective studies evaluating powered exoskeletons in SCI patients, to date, not a single well-designed, randomized clinical trial has been published. However, there is evidence for beneficial effects of over-ground exoskeleton therapy on walking func…
Phase: NA • Sponsor: Mario Widmer • Aim: Symptom relief
Last updated Jun 27, 2026 08:05 UTC
-
New surgical technique could cut bladder cancer recurrence
Disease control CompletedAim: To compare the surgical method of En Bloc resection to the conventional transurethral resection of non-muscle invasive bladder cancer (NMIBC) in terms of complete removal of tumour, specimen quality, and pathological certainty. Background: NMIBC is a common disease with a 5…
Phase: NA • Sponsor: Jørgen Bjerggaard Jensen • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New combo therapy aims to tame stem cell transplant complications
Disease control CompletedThis is a single-arm, phase I/II, study of PTCy/sirolimus plus VIC-1911 to prevent GVHD and relapse after Allogeneic Hematopoietic Cell Transplantation (alloHCT).
Phase: PHASE1, PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Brain zaps may boost social skills in autism
Symptom relief Recruiting nowThis is a randomized interventional study designed to evaluate the effects of repetitive Transcranial Magnetic Stimulation (rTMS) on neural and behavioral facets of social cognition in adults with autism spectrum disorder (ASD).
Phase: NA • Sponsor: Yale University • Aim: Symptom relief
Last updated Jun 27, 2026 09:03 UTC
-
New hope for adults with rare leukemia: drug combo shows promise in early trial
Disease control OngoingThis phase I trial tests the safety, side effects, and best dose of venetoclax in combination with a pediatric-inspired chemotherapy regimen known as C10403 in treating patients with newly diagnosed B cell acute lymphoblastic leukemia. Venetoclax may stop the growth of cancer cel…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Can a clotting gauze and drug cut blood loss in knee surgery?
Disease control CompletedThis study is to conduct a prospective randomized controlled trial to investigate the blood-conservation effect of combination of intravenous TXA and QCG in a primary TKA procedure.
Phase: PHASE4 • Sponsor: Chang Gung Memorial Hospital • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug duo aims to outsmart melanoma that resists standard treatment
Disease control OngoingThe main goal of this study is to establish the proportion of patients with objective response to zimberelimab/domvanalimab in PD-1 R/R melanoma patients.
Phase: PHASE2 • Sponsor: Diwakar Davar • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Pictographs in electronic health records aim to stop wrong-patient errors in newborn ICUs
Prevention Recruiting nowNewborns in the neonatal intensive care unit (NICU) are at high risk for wrong-patient errors. Effective 2019, The Joint Commission requires that health systems adopt distinct methods of newborn identification as part of its National Patient Safety Goals. Displaying patient photo…
Phase: NA • Sponsor: Columbia University • Aim: Prevention
Last updated Jun 27, 2026 11:02 UTC
-
Heart valve drug shows promise in preventing brain and kidney damage
Prevention CompletedThe aim of this trial is to assess the safety and efficacy of conestat alfa (Ruconest®, Pharming Technologies B.V.) on renal and cerebral ischemic events in patients undergoing TAVI for severe symptomatic aortic stenosis (AS) compared to placebo.
Phase: PHASE2 • Sponsor: University Hospital, Basel, Switzerland • Aim: Prevention
Last updated Jun 27, 2026 12:23 UTC
-
Can a sedative shield livers from transplant damage?
Prevention Ongoingthe aim of the study is to approve the hypothesis that dexmedetomidine can protect against glycocalyx degradation induced by hepatic ischemia-reperfusion injury and hence can reduce the subsequent complications as early allograft dysfunction, other organ dysfunction and hemodynam…
Phase: PHASE4 • Sponsor: Assiut University • Aim: Prevention
Last updated Jun 27, 2026 07:52 UTC
-
New radiation technique aims to slash gut damage in bladder cancer patients
Disease control OngoingThis is a single-arm, prospective, Phase II, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for muscle invasive bladder cancer will translate into a decreased rate of acute gastrointestinal toxicity compared with the historically reported rate for …
Phase: NA • Sponsor: Varian, a Siemens Healthineers Company • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Targeted drug shows promise for rare genetic cancers
Disease control TerminatedThe purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors and a pathogenic or likely pathogenic tumor PALB2 (tPALB2) mutation.
Phase: PHASE2 • Sponsor: Tempus AI • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Can a drug prevent gut problems and pneumonia in Brain-Injured patients?
Disease control TerminatedImpaired gastrointestinal transit (IGT) especially constipation, is common among patients under mechanical ventilation, occurring in up to 80 % of the patients during the first week, and has been associated with worse outcome in intensive care unit (ICU). Although IGT in critical…
Phase: PHASE3 • Sponsor: University Hospital, Brest • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC